Target intelligence / Profile preview

Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial (PDHA1)

Target
PDHA1
Molecular classification
Enzyme, Oxidoreductase, Mitochondrial matrix protein
01

Overview

Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial (PDHA1), is an essential mitochondrial enzyme subunit responsible for catalyzing the oxidative decarboxylation of pyruvate to acetyl-CoA, the crucial step linking glycolysis to the TCA cycle and cellular energy production. The enzyme is a heterotetramer consisting of two alpha and two beta subunits. PDHA1 mutations cause pyruvate dehydrogenase complex deficiency, leading to metabolic and neurological disorders due to impaired ATP generation. The activity of the PDH complex is regulated by phosphorylation, cofactors (notably thiamine pyrophosphate), and pharmacological modifiers. It is a well-studied target for the treatment of inherited and acquired metabolic diseases.

Other names
PDHA1PDHAPDHCE1APHE1APDHE1-A type Ipyruvate dehydrogenase (lipoamide) alpha 1pyruvate dehydrogenase alpha 1pyruvate dehydrogenase E1 alpha 1 subunitpyruvate dehydrogenase complex, E1-alpha polypeptide 1pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial
02

Mechanism of action

Allosteric activation or stabilization of the enzyme complex; Cofactor supplementation (thiamine to enhance enzyme activity); Pharmacological activation (dichloroacetate inhibits pyruvate dehydrogenase kinase, activating the complex)

03

Biological functions

Energy metabolismCatalysis of pyruvate oxidative decarboxylationAcetyl-CoA biosynthesis from pyruvateATP productionLinking glycolysis to the tricarboxylic acid (TCA) cycle
04

Disease associations

Metabolic disorders (particularly pyruvate dehydrogenase deficiency)Neurological diseaseLactic acidosisNeurodegenerative disease (by association with metabolic dysfunction)Other mitochondrial disorders
05

Safety considerations

Thiamine deficiencyHyperlactatemiaProlonged enzyme inhibition or activation can disrupt cellular energy balancePotential for neurological and metabolic side effects in treatments targeting this enzyme
06

Interacting drugs

Dichloroacetate

3 more in the full profile.

07

Biomarkers

Blood lactate (to monitor pyruvate dehydrogenase deficiency)Acetyl-CoA/pyruvate levelsPyruvate/lactate ratioGenetic testing for PDHA1 mutations in suspected cases

Beyond the preview

Go deeper on Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial (PDHA1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial (PDHA1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call